Manisha Garg, MD
Endocrinology, Diabetes & Metabolism · Montgomery, ALNPI 1215215389
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 462 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Abbott$760
- Dexcom, Inc.$503
- Mannkind Corporation$433
- Boehringer Ingelheim$410
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,222100%
- Education$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 89 | $1,405 |
| Novo Nordisk | 61 | $1,129 |
| Abbott | 51 | $760 |
| Dexcom, Inc. | 36 | $503 |
| Mannkind Corporation | 19 | $433 |
| Boehringer Ingelheim | 26 | $410 |
| Xeris Pharmaceuticals, Inc. | 18 | $379 |
| Sanofi-aventis U.S. LLC | 18 | $350 |
| Tandem Diabetes Care, Inc. | 12 | $281 |
| AstraZeneca(2 entities) | 15 | $258 |
| AbbVie | 13 | $240 |
| Medtronic(2 entities) | 10 | $226 |
| Amgen(2 entities) | 11 | $187 |
| BETA Bionics, Inc. | 10 | $182 |
| Corcept Therapeutics | 10 | $180 |
| Amneal Pharmaceuticals LLC | 9 | $143 |
| Kyowa Kirin, Inc. | 5 | $101 |
| IBSA Pharma Inc. | 5 | $101 |
| Radius Health, Inc. | 3 | $98 |
| Intuitive Surgical | 1 | $92 |
| Insulet Corporation | 5 | $92 |
| Amarin Pharma, Inc. | 5 | $92 |
| Bayer | 2 | $86 |
| Novartis | 5 | $78 |
| Ascendis Pharma Endocrinology Inc | 3 | $67 |
| Antares Pharma, Inc. | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Pfizer | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Merck | 2 | $27 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $23 |
| Rhythm Pharmaceuticals, Inc. | 1 | $21 |
| Lifescan, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Companion Medical, Inc. | 1 | $13 |
How this compares
$8,222 in reported general payments places this provider in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 417 | $607,641 |
| MounjaroTirzepatide | 370 | $570,515 |
| JardianceEmpagliflozin | 178 | $200,931 |
| TrulicityDulaglutide | 127 | $184,709 |
| Tresiba Flextouch U-200Insulin Degludec | 109 | $99,174 |
| JanuviaSitagliptin Phosphate | 99 | $91,535 |
| FarxigaDapagliflozin Propanediol | 71 | $77,295 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $64,343 |
| Humulin R U-500Insulin Regular, Human | 19 | $59,796 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 52 | $54,784 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $49,200 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $46,676 |
| RybelsusSemaglutide | 26 | $43,622 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $41,413 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $39,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,405 | $764,142528 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,129 | $661,653472 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Tradjenta, Synjardy | $410 | $297,821261 claims |
| MerckJanuvia, Janumet Xr, Janumet | $27 | $142,036158 claims |
| AstraZenecaFarxiga | $258 | $77,29571 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $350 | $41,41342 claims |
| AbbVieSynthroid | $240 | $17,619156 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $101 | $12,19745 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $143 | $8,860508 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $51 | $6,56615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Montgomery
- Hima AmmanaMontgomery$9K
- Warda NiazMontgomery$8K
- Vaishall ThudiMontgomery$8K
- Elaina AdderleyMontgomery$7K
- Ahsan FarooqMontgomery$4K
- Mohammad-Ehsan OwrangiMontgomery$3K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.